This article is reprinted from Brilliant Pharmaceutical Group

On February 28, 2019, Shanghai OPM Biosciences Co., Ltd. (hereinafter referred to as "Shanghai OPM") and Chengdu Brilliant Pharmaceutical Group (hereinafter referred to as "Brilliant") reached a strategic cooperation agreement in Chengdu to cooperate in the early research, CMC technology and large-scale production of Biomacromolecule.

Dr. Xiao Zhihua, President and General Manager of OPM, Vice-Chairman of Sichuan International Medical Exchange and Promotion Association, and Su Zhonghai, President of Chengdu Brilliant, attended the scene. The two sides had a profound, pragmatic and detailed communication and witnessed the signing of the cooperation agreement.

Left: Dr. Xiao Zhihua  Right: President Su Zhonghai

In line with the principles of honesty, win-win cooperation and  complementary advantages, Shanghai OPM provides the best implementation path for promoting Brilliant's rapid development, project transformation, pipeline optimization and cost control in the field of  Biomacromolecule, helping accelerates the realization of the vision of "strategic transformation" of Chengdu Brilliant.

The whole signing ceremony ended in a friendly atmosphere,  demonstrating the determination of the two companies to join  hands in exploiting biomacromolecule, and also witnessing the historic moment when Brilliant entered the field of biomacromolecule. The two saides will join hand in hand to strengthen cooperation with each other. 

About Brilliant

In today's era of pharmaceutical reform,Brillinat stands out in the consistency evaluation. Tenofovir and Cefuroxime Axetil were first approved and successfully won the National "4 + 7" Cities Drug Purchasing Mode.

At the same time, BT-1053, an innovative drug with independent intellectual property rights, passed the implicit permission for clinical trials quickly, and obtained the first batch of construction units for production of shortage drugs, which was jointly promulgated by the four State Ministries and Committees (a consortium of Shanghai medicines, Chinese medicines and Brilliant). It marks that Chengdu Brilliant has taken a solid step in the cluster development of generic drugs as well as independent research and development of innovative drugs, initially realizing the strategic transformation of Brilliant.

Chengdu Brilliant Pharmaceutical Group

Adhering to the business concept of "Extensive Expansion + Intensive Development", Brilliant adopted a new strategic measure of "imitation escort, innovative and rapid development". In order to quickly achieve the vision of Brilliant's innovation transformation, it devotes 40% of its market sales to R&D every year, engaging itself in the development of innovative small molecules and biological macromolecules. We sincerely  invite innovative leading enterprises to reach a united front alliance, welcoming outstanding talents at all levels to join  Brilliant Pharmaceutical Group, share Brilliant, and join this grand project together.

For more detailed recruitment information, please send e-mails to:brilliant.hr@btyy.com

Tel: 13540832040 Mr. Chen (the same number as Wechat)

15283792167 Ms. Tang (the same number as Weichat)

About Shanghai OPM

Shanghai OPM Biosciences Co., Ltd. was registered in Shanghai International Medical Park in November 2013. OPM, from Optimize, is committed to "optimizing cell culture  technology" with the vision of building a high-quality brand of  Chinese culture medium. With its own culture medium development technology and international advanced concepts, OPM provides high-quality culture medium products and development services for enterprises and research institutes which are engaged in the development and production of biopharmaceuticals, vaccines and cell therapy.

OPM

OPM team brings together a group of senior experts to provide professional technical services to customers. With high-quality media products, it has gained good reputation in the industry  and won the trust of customers. OPM has won many honors and awards, and has been awarded "High-tech Enterprises", "Most Potential Enterprises  for Overseas Students" and "Excellent Enterprises in China Innovation and Entrepreneurship Competition".

Sureness Biosciences, located at No. 3 Building, 100 Lane, Banxia Road, Shanghai International Medical Park, is a           one-stop CDMO service platform for R&D and production of therapeutic biopharmaceuticals, which is built by OPM, Dachen Capital and Huaxing Capital,

On the basis of the existing platform for developing and producing culture medium in OPM, Silun Biology will be the first one in Shanghai International Medical Park to realize the substitution of imported culture medium, starting with gene sequence, stabilizing cell line establishment, upstream and downstream process development, and pilot scale production of GMP (200L-500L), to the domestic and foreign declaration  of one-stop R&D  and production CDMO service platform for therapeutic antibody drug, providing a complete solution from antibody DNA to IND to biopharmaceutical enterprises.

Its GMP production strictly conforms to international and Chinese GMP standards, including those of China Food and Drug Administration, United States Food and Drug  Administration (21 CFR), European Drug Administration (Eudralex), WHO, PIC/S and ICH.